Navigation Links
Novavax Reports First Quarter 2009 Financial Results

per share from discontinued operations $- $(0.01) Net loss per share $(0.12) $(0.13)

                           SELECTED BALANCE SHEET DATA
                                 (in thousands)

                                             As of March 31,   As of December
                                                 2009              31, 2008
    Cash and cash equivalents                   $19,629            $26,938
    Short-term investments                        5,958              6,962
    Total current assets                         26,642             35,096
    Working capital                                (190)             7,379
    Total assets                                 67,962             76,625
    Long term debt                                  468                480
    Stockholders' equity                         37,794             76,625

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
(Date:1/22/2015)... San Diego, California (PRWEB) January 22, 2015 ... R Promotional Offer to their comprehensive portfolio of ... Offer allows customers to purchase a Centrifuge 5424/5424 R ... Pipette Bundle of either Eppendorf Research plus or Eppendorf ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Controlled Substance ... Alliance, which helps companies check the legal requirements around ... expand to China. , As their international operations ... globally adopting software solutions built as a result of ...
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... "We are pleased to ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at 2Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2
... Next Generation Cellulosic Feedstock Program, KINGSTON, ... Inc. (PPI) has,announced today that it has ... non-food crops for industries seeking renewable,feedstocks for ... The facility, located in Waterloo, New York, ...
... -, BRIDGEWATER, N.J. and NEW YORK, June 18 ... launch backed by Warburg Pincus, the leading global private ... GANIC from Warburg,Pincus Private Equity X, L.P., a $15 ... was founded by a highly seasoned group of senior,executives ...
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that ... present at the,Jefferies & Co. 2nd Annual Healthcare Conference ... June 25, 2008., An audio webcast of Dr. ... webcast at: . An archived version of ...
Cached Biology Technology:Performance Plants Establishes U.S. Biofuels Facility 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 3
(Date:12/17/2014)... Markets ( ) has announced the ... Button Synaptics Fingerprint Sensor Technology Analysis" report to ... Based on a totally different sensing technology ... time a fingerprint sensor in its product. ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming ... than at international borders. Over the past decade, ePassports, ... travelers to self process through border control via eGates ... number of airports, seaports, and land borders across the ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global leader ... series of digital telemetry implants to meet the ... part of the PhysioTel™ Digital platform, was designed ... data when incorporating functional endpoints into repeat-dose toxicology ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... of the debate in Alzheimer,s disease (AD) has focused on ... symptom or the cause of the disease. But George ... have pursued another hypothesis: much earlier interactions between the two ... "cell cycle re-entry" (CCR). Dr. Bloom will present ...
... drug that targets macrophages, a type of immune cells, ... multiforme decreased the cancer,s growth and extended survival of ... Tuesday Dec. 17, at the American Society for Cell ... rates of apoptosis, or programmed cell death, were higher ...
... outstanding work of five young researchers from China, Chinese ... Young Investigator Awards, valued at 1,000 USD each, were ... the 4th Asia-Pacific Osteoporosis Meeting by researchers under the ... the Hong Kong Convention and Exhibition Centre, is one ...
Cached Biology News:Uncovering first molecular missteps that drive neurons in pathway leading to Alzheimer's disease 2Blocking tumor-associated macrophages decreased glioblastoma's growth & extended survival in mice 2Young investigators awarded for research excellence at Hong Kong meeting 2
... Custom monoclonal antibody development to targets ... small molecules, DNA, and cancer-specific surface antigens. ... phases and is completed in approximately 40 ... the nature of antigens). Phase I: ...
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
US Pharmacopoeia Purified-Water/Water-for-Injection Quality Water...
Biology Products: